Vaccines Market, By Type (Monovalent Vaccines , Multitvalent Vaccines), By Technology (Conjugate Vaccines, Recombinant Vaccines, Inactivated and Subunit Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Other Vaccine Technologies), By Disease Indicatio

Vaccines Market, By Type (Monovalent Vaccines , Multitvalent Vaccines), By Technology (Conjugate Vaccines, Recombinant Vaccines, Inactivated and Subunit Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Other Vaccine Technologies), By Disease Indication (Pneumococcal Disease, Influenza, Combination Vaccines, HPV, Meningococcal Disease, Herpes Zoster, Rotavirus, MMR, Varicella, Hepatitis, DTP, Polio, RSV, Other Disease Indications), By Route of Administration (Intramuscular, Subcutaneous, Oral, Intranasal), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

The global vaccines market has been witnessing steady growth over the past few years due to the rising prevalence of various infectious diseases and technological advancements in vaccine production. Vaccines aid in building immunity against specific diseases and allow populations at risk to be protected from the life-threatening effects of dangerous infections. Growing awareness about immunization, especially in developing nations is propelling the demand for advanced and affordable vaccines globally. Furthermore, the introduction of combination vaccines by major manufacturers is encouraging higher vaccination rates and reducing the burden on healthcare resources. Continued support from governments and international organizations towards immunization programs is expected to drive the global vaccines market growth during the forecast period.

Market Dynamics:

The global vaccines market is primarily driven by the rising incidence of infectious diseases, technological advancements in vaccine production, and growing focus on immunization programs by governments. According to the World Health Organization (WHO), immunization averts an estimated 2-3 million deaths annually. Mandates on vaccination of certain diseases and worldwide efforts towards disease eradication also provide momentum to market growth. However, high R&D costs associated with new vaccine development, stringent regulatory approvals, and vaccine hesitancy due to misinformation are some of the factors hindering the widespread adoption of vaccines. On the other hand, development of thermostable vaccines that can withstand high temperatures without refrigeration, cell-based vaccine technologies offering protection against mutating viruses, and initiatives to drive vaccine uptake in low and middle-income countries are expected to unlock lucrative opportunities for players in the coming years.

Key features of the study:

• This report provides in-depth analysis of the global vaccines market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global vaccines market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Pfizer, Merck, Sanofi Pasteur, GlaxoSmithKline (GSK), AstraZeneca, Johnson & Johnson, CSL Limited, and Serum Institute of India
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global vaccines market.

Detailed Segmentation-

• By Type Insights (Revenue, USD Bn, 2019 - 2031)
• Monovalent Vaccines
• Mulitvalent Vaccines
• By Technology Insights (Revenue, USD Bn, 2019 - 2031)
• Conjugate Vaccines
• Recombinant Vaccines
• Inactivated and Subunit Vaccines
• Live Attenuated Vaccines
• Toxoid Vaccines
• Other Vaccine Technologies
• By Dosage Form Insights (Revenue, USD Bn, 2019 - 2031)
• Tablets/Capsules
• Liquids
• Creams
• Gels
• Others
• By Disease Indication Insights (Revenue, USD Bn, 2019 - 2031)
• Pneumococcal Disease
• Influenza
• Combination Vaccines
• HPV
• Meningococcal Disease
• Herpes Zoster
• Rotavirus
• MMR
• Varicella
• Hepatitis
• DTP
• Polio
• RSV
• Other Disease Indications
• By Route Of Administration: Insights (Revenue, USD Bn, 2019 - 2031)
• Intramuscular
• Subcutaneous
• Oral
• Intranasal
• By Regional Insights (Revenue, USD Bn, 2019 - 2031)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• GlaxoSmithKline plc (GSK)
• Merck & Co., Inc.
• Pfizer Inc.
• Sanofi
• Moderna, Inc.
• AstraZeneca
• Johnson & Johnson
• Novavax, Inc.
• CSL Limited
• Emergent BioSolutions Inc.
• Bharat Biotech
• Serum Institute of India
• BioNTech SE
• Takeda Pharmaceutical Company
• Sinovac Biotech Ltd.
• Sinopharm (China National Pharmaceutical Group)
• Vaxart, Inc.
• Inovio Pharmaceuticals, Inc.
• Valneva SE
• Vaccitech plc